Exciting are the Q2 2018 reported results by Exelixis’ (EXEL) including the firm’s revenues and earnings, compared to 2017. Impressive were Cabometyx’ (cabozantinib) revenues, in addition to the milestone payments from collaborating companies and ex-USA marketing agent. Inspiring also are the efforts the firm is spending on research and development with the aim of further boosting its revenues.
Of the Results
Revenues and Incomes
– Total revenues for the quarter were $186.1 million, compared to $99.0 million for the comparable period in 2017. These revenues . . .